Inter-observer agreement in describing the ultrasound appearance of adnexal masses and in calculating the risk of malignancy using logistic regression models.

Research output: Contribution to journalArticle

Standard

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Inter-observer agreement in describing the ultrasound appearance of adnexal masses and in calculating the risk of malignancy using logistic regression models.

AU - Sladkevicius, Povilas

AU - Valentin, Lil

PY - 2015

Y1 - 2015

N2 - Purpose: To estimate inter-observer agreement with regard to describing adnexal masses using the International Ovarian Tumor Analysis (IOTA) terminology and the risk of malignancy calculated using IOTA logistic regression models LR1 and LR2, and to elucidate what explained the largest inter-observer differences in calculated risk of malignancy. Experimental Design: 117 women with adnexal masses were examined with transvaginal gray scale and power Doppler ultrasound by two independent experienced sonologists who described the masses using IOTA terminology. The risk of malignancy was calculated using LR1 and LR2. A predetermined risk of malignancy cutoff of 10% indicated malignancy. Results: There were 94 benign, four borderline and 19 invasively malignant tumors. There was substantial variability between the two sonologists in measurement results and some variability in assessment of categorical variables (agreement 40-98%, Kappa 0.30-0.91). Inter-observer agreement when classifying tumors as benign or malignant was 84% (98/117), Kappa 0.68 for LR1, and for LR2 85% (99/117), Kappa 0.68. When using LR1 and LR2 the inter-observer difference in calculated risk was >25 percentage units in 9% (11/117) and 12% (14/117) of tumors, respectively. Differences in assessment of wall irregularity, acoustic shadowing, color score and color flow in papillary projections explained most of these largest differences. Conclusions: Inter-observer agreement in classifying tumors as benign or malignant using the risk of malignancy cut off of 10% for LR1 and LR2 was good. However, because risks estimates may differ substantially between sonologists one should be cautious with using the risk value for counseling patients about their individual risk.

AB - Purpose: To estimate inter-observer agreement with regard to describing adnexal masses using the International Ovarian Tumor Analysis (IOTA) terminology and the risk of malignancy calculated using IOTA logistic regression models LR1 and LR2, and to elucidate what explained the largest inter-observer differences in calculated risk of malignancy. Experimental Design: 117 women with adnexal masses were examined with transvaginal gray scale and power Doppler ultrasound by two independent experienced sonologists who described the masses using IOTA terminology. The risk of malignancy was calculated using LR1 and LR2. A predetermined risk of malignancy cutoff of 10% indicated malignancy. Results: There were 94 benign, four borderline and 19 invasively malignant tumors. There was substantial variability between the two sonologists in measurement results and some variability in assessment of categorical variables (agreement 40-98%, Kappa 0.30-0.91). Inter-observer agreement when classifying tumors as benign or malignant was 84% (98/117), Kappa 0.68 for LR1, and for LR2 85% (99/117), Kappa 0.68. When using LR1 and LR2 the inter-observer difference in calculated risk was >25 percentage units in 9% (11/117) and 12% (14/117) of tumors, respectively. Differences in assessment of wall irregularity, acoustic shadowing, color score and color flow in papillary projections explained most of these largest differences. Conclusions: Inter-observer agreement in classifying tumors as benign or malignant using the risk of malignancy cut off of 10% for LR1 and LR2 was good. However, because risks estimates may differ substantially between sonologists one should be cautious with using the risk value for counseling patients about their individual risk.

U2 - 10.1158/1078-0432.CCR-14-0906

DO - 10.1158/1078-0432.CCR-14-0906

M3 - Article

C2 - 25424853

VL - 21

SP - 594

EP - 601

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -